When Paul Hudson takes over from Olivier Brandicourt as chief executive of Sanofi this week, he will be among the few non-French executives at the helm of a major corporation in the country, reported Bloomberg.
According to the news source, investors will judge the British citizen not on his accent, but his ability to fire up the drugmaker's R&D operations, expand in the lucrative but competitive oncology market and tack through pricing headwinds.
The former pharmaceuticals head at Novartis is credited with rolling out drugs such as Cosentyx for psoriasis. In his new role, Hudson will need to deliver more blockbusters to reduce Sanofi's reliance on Dupixent, its medicine for severe eczema and asthma, the news source said.
Bloomberg said that during the Brandicourt era, Sanofi's track record with acquisitions was "mixed," but more deals would be the fastest way to build up Sanofi's offering of medicines and profile in cancer, analysts at HSBC have said.
Meanwhile, the new CEO points to Sanofi treatments for multiple myeloma, breast cancer and rare blood disorders, along with a vaccine for respiratory syncytial virus, as some of the most promising opportunities.
Hudson is also signaling bolder ambitions in China, partly through tech partnerships. In the coming months, he also plans to carry out a "deep dive" of the pipeline and closely examine how each unit, including consumer health, fits within the company, the news source said.
To read more NewsPoints articles, click here.